Counterfeit GLP-1 medicine is not a hypothetical: the FDA has seized fake Ozempic pens from the legitimate US supply chain three times since December 2023. Each time it published a notice with the lot number and the features that distinguish the fake. This page sets those notices side by side, adds the World Health Organization's alert and the one non-GLP-1 weight-loss counterfeit notice we found, and counts what reaches the FDA's adverse-event database under the "counterfeit" codes. It is a record of what regulators and manufacturers have published, read on 20 November 2026.
A counterfeit is a product that claims to be a specific authentic medicine and is not. That is a different problem from compounded semaglutide or products sold "for research use", which are unapproved but do not pretend to be Ozempic. The distinction matters because the warning signs are different.
The three FDA notices, side by side
| Notice date | Product | Lot and serial | How much | What was counterfeit | Adverse events FDA knew of |
|---|---|---|---|---|---|
| 21 December 2023 | Ozempic 1 mg injection | Lot NAR0074, serial 430834149057 | "Thousands of units" seized | Needles (sterility unconfirmable), pen label, patient and prescriber information, carton | Five, none serious, consistent with authentic Ozempic's common reactions |
| 14 April 2025 | Ozempic 1 mg injection | Lot PAR0362, serial beginning 51746517 | "Several hundred units", seized 9 April 2025 after Novo Nordisk notified FDA on 3 April | Not yet known at notice; testing under way | Six, none appearing linked to the counterfeit |
| 5 December 2025 | Ozempic 1 mg injection | Lot PAR1229, which is also a genuine lot | "Dozens of units" seized | Pen label layout: "EXP/LOT" printed to the left of the expiry and lot, instead of above them | Six, all associated with authentic Ozempic, all reported by Novo Nordisk |
Source: FDA, FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain, page current as of 5 December 2025, read 20 November 2026. All three notices concern product distributed outside Novo Nordisk's authorised supply chain that nonetheless reached the legitimate chain.
Three things change across the three notices. The quantity fell, from thousands of units to dozens. The fakes became harder to tell from the real thing: in 2023 the counterfeit carried its own invented serial number and visibly different needles; by December 2025 it copied a genuine lot number, so that the only published tell was where two words sat on a label. And for one group FDA drew a line explicitly: people who received PAR1229 pens through Novo Nordisk's patient assistance programme were told their pens were authentic.
What the December 2023 needles showed
Novo Nordisk's statement of 21 December 2023, updated 20 February 2024, describes the difference. On a genuine needle the paper tab carries the needle's own lot number (ME61216 in the photographed example), reads "NovoFine Plus", and has a transparent inner cover. On the counterfeit the tab carried the carton's lot number, NAR0074, read "NovoFine", and the inner cover was tinted blue. The fake needle's sterility could not be confirmed, which FDA said "presents an increased risk of infection". Novo Nordisk asked people holding that lot to return it through its customer-care line.
What the pens contained
No test result has been published. FDA's notices for all three lots say testing of the seized products was under way and that the agency did not yet have information about their identity, quality or safety; none of the dated updates on the page reports a finding. The WHO's 2024 statement describes the range of possibilities for falsified semaglutide in general: a product lacking the active ingredient could leave blood sugar or weight unmanaged, and an undeclared active ingredient "e.g. insulin" could cause "an unpredictable range of health risks". That is a description of risk, not a finding about these lots.
Outside the United States: the WHO alert
On 20 June 2024 the WHO issued its first alert on falsified semaglutide (Medical Product Alert 2/2024). It covered three falsified Ozempic batches: detected in Brazil in October 2023, the United Kingdom in October 2023 and the United States in December 2023 — the last being the NAR0074 lot above. The WHO said its Global Surveillance and Monitoring System had observed "increased reports on falsified semaglutide products in all geographical regions since 2022", and linked the rise to demand outstripping supply. The shortage record on this site dates that supply squeeze.
What FDA's adverse-event database shows
The FDA Adverse Event Reporting System (FAERS) codes some reports with a product-problem term. Using the openFDA interface (data to 28 October 2026), we counted reports that name the drug and carry "suspected counterfeit product" or "product counterfeit":
| Molecule | Reports with either counterfeit term | "Suspected counterfeit product", by year received | All reports naming the molecule |
|---|---|---|---|
| Semaglutide | 76 | 2021: 1 · 2022: 1 · 2023: 11 · 2024: 25 · 2025: 20 · 2026 to date: 11 | 78,023 |
| Tirzepatide | 52 | 2022: 1 · 2023: 1 · 2024: 6 · 2025: 12 · 2026 to date: 26 | 181,068 |
| Liraglutide | 8 suspected, plus 1 "product counterfeit" report from 2012 | 2021: 1 · 2022: 2 · 2023: 2 · 2024: 0 · 2025: 2 · 2026 to date: 1 | not counted |
Read these counts as a floor and as suspicions. A report is filed by a patient, clinician or manufacturer who suspects a problem; it is not a laboratory confirmation. Counts depend on who reports (manufacturers' patient-support programmes file many reports), and reports in which the drug's name could not be matched to the openFDA fields are not included. The two terms overlap, so the first column counts each report once. With those limits stated, the one pattern the data shows clearly is direction: semaglutide's suspected-counterfeit reports peaked in 2024, while tirzepatide's have doubled each year since 2024. FDA has published no counterfeit-tirzepatide notice; the database records that the suspicion exists, not that the product does.
Not only injections
Weight-loss counterfeits are not confined to GLP-1 pens. On 20 June 2025 Haleon, the maker of Alli, issued a public notice that counterfeit Alli capsules had been sold by US online retailers outside its authorised supply chain. Haleon's notice identifies them by lot number 5601182 printed with an expiry date later than July 2025 (the genuine lot expires July 2025), and describes authentic capsules as carrying a dark blue band printed "Orlistat" and "60", with a foil seal under the cap. FDA's general counterfeit-medicine page links to the notice.
How regulators say a counterfeit is spotted
FDA's general guidance on counterfeit medicine (page current as of 16 October 2026) lists three warning signs: packaging that looks different from what is normally received, a new or unusual side effect after use, and purchase from an online pharmacy. It points buyers to state-licensed pharmacies and to its BeSafeRx programme. The WHO's advice in its 2024 statement is similar: a prescription from a licensed physician, avoiding unfamiliar or unverified sources, checking packaging and expiry, and refrigerated storage for injectable semaglutide (storage rules are on our pen storage page).
What none of this guidance can do is identify a well-made fake by eye. The December 2025 counterfeit carried a genuine lot number. The reliable checks named by FDA and the manufacturers are the channel the pen came through — an authorised distributor and a state-licensed pharmacy — and, for a specific pen in doubt, the pharmacist or the manufacturer's customer-care line. The makers' own direct-pharmacy routes are described on NovoCare Pharmacy and LillyDirect.
What this page does not cover
- Compounded and "research" products. They are unapproved drugs rather than counterfeits; FDA's warnings about them, and the warning letters it has sent, are covered on compounded semaglutide and compounded tirzepatide vs Zepbound. Peptifact keeps a warning-letter tracker of vendors selling research-labelled GLP-1s.
- Supplements sold as "GLP-1", which contain no GLP-1 drug; see GLP-1 supplements.
- Anything about a specific pen. This page cannot say whether any product is genuine. Anyone who suspects a counterfeit can report it to FDA's MedWatch programme, and FDA asks that suspected criminal sales be reported to its Office of Criminal Investigations.
Sources
- FDA. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain — updates dated 21 December 2023, 14 April 2025 and 5 December 2025; page current as of 5 December 2025; read 20 November 2026.
- FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss — current as of 1 October 2026; read 20 November 2026.
- FDA. Counterfeit medicine — current as of 16 October 2026; read 20 November 2026.
- Novo Nordisk US. Update: Novo Nordisk warns consumers about counterfeit Ozempic (semaglutide) injection 1 mg in the U.S. — 21 December 2023, updated 20 February 2024; read 20 November 2026.
- World Health Organization. WHO issues warning on falsified medicines used for diabetes treatment and weight loss — 20 June 2024 (Medical Product Alert 2/2024); read 20 November 2026.
- Haleon. Public notification: counterfeit alli (orlistat) capsules found at U.S. online retailers — issued 20 June 2025; read 20 November 2026.
- FDA Adverse Event Reporting System via the openFDA drug event API (data last updated 28 October 2026), queries by generic name and the MedDRA terms "Suspected counterfeit product" and "Product counterfeit" — counted 20 November 2026.
